IFNA1 and systemic lupus erythematosus: In a phase Ib randomized controlled trial of sifalimumab, a human anti-IFNα monoclonal antibody that specifically neutralizes most IFNα subtypes, SLE disease activity decreased in patients with high IGS at baseline in the combined sifalimumab group compared to placebo.